Frenova Renal Research | Nephrology Associates, P.A.
Research site
Site insights
Top conditions
Top treatments
LNP023
BI 685509
Parent organization
This site is a part of Frenova Renal Research
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Active trials
3 of 7 total trials
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...
Enrolling
Primary IgA Nephropathy
Drug: LNP023
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...
Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a...
Active, not recruiting
IgA Nephropathy
Drug: Placebo
Drug: LNP023
Trial sponsors
C
P
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems